产品介绍 FAQs 评论(0)
宿主来源
Rabbit抗原名称
CXCL9/MIG分子别名
C-X-C motif chemokine 9; Gamma-interferon-induced monokine; Monokine induced by interferon-gamma (HuMIG; MIG); Small-inducible cytokine B9; CMK; MIG; SCYB9免疫原
Recombinant Protein细胞定位
SecretedAccession
Q07325克隆号
S-1314-35抗体类型
Recombinant mAb抗体同种型
IgG反应种属 ?
Hu纯化方式
Protein A浓度
0.5 mg/ml标记
Unconjugated性状
Liquid缓冲体系
PBS, 40% Glycerol, 0.05% BSA, 0.03% Proclin 300
储存条件
12 months from date of receipt / reconstitution, -20 °C as supplied
应用
ICC ?
WB
IP
稀释度
应用 稀释度 WB 1:1000 IP 1:50 ICC 1:500
CXCL9, also known as MIG (monokine induced by interferon-gamma), is a member of the ELR-negative CXC chemokine subfamily that is inducible by IFN-γ. It plays a pivotal role in immune regulation and inflammation, and is implicated in various diseases, including cancer. CXCL9 is known to bind to its receptor CXCR3, facilitating the recruitment of CXCR3+ cells such as effector T cells, regulatory T cells (Tregs), and CD8+ cytotoxic T cells. This chemokine is involved in the pathogenesis of several physiological conditions, including its role in tumor growth, angiogenesis, and metastasis. In the context of cancer, CXCL9 has been identified as a potential biomarker and therapeutic target. It is suggested that the CXCL9/CXCR3 axis can be leveraged for cancer treatment by promoting the infiltration of immune cells to the tumor site, thereby enhancing anti-tumor immunity. Additionally, the expression levels of CXCL9 have been associated with the prognosis of certain cancers, indicating its potential as a prognostic indicator. Furthermore, research has highlighted the complex role of CXCL9 in the tumor microenvironment (TME). It can act as both an immunoactivator, promoting the recruitment of immune cells to combat tumor cells, and as a promoter of tumor growth and metastasis through autocrine signaling in certain contexts.
免疫印迹
WB result of CXCL9/MIG Recombinant Rabbit mAb
Primary antibody: CXCL9/MIG Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: untreated THP-1 whole cell lysate 20 µg
Lane 2: THP-1 treated with 200 ng/ml IFN-gamma and 50 ng/ml LPS for 24 hours whole cell lysate 20 µg
Secondary antibody: Goat Anti-rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 14 kDa
Observed MW: 15 kDa
免疫沉淀
CXCL9/MIG Rabbit mAb at 1/50 dilution (1 µg) immunoprecipitating CXCL9/MIG in 0.4 mg THP-1 treated with 200 ng/ml IFN-gamma and 50 ng/ml LPS for 24 hours whole cell lysate.
Western blot was performed on the immunoprecipitate using CXCL9/MIG Rabbit mAb at 1/1000 dilution.
Secondary antibody (HRP) for IP was used at 1/1000 dilution.
Lane 1: THP-1 treated with 200 ng/ml IFN-gamma and 50 ng/ml LPS for 24 hours whole cell lysate 20 µg (Input)
Lane 2: CXCL9/MIG Rabbit mAb IP in THP-1 treated with 200 ng/ml IFN-gamma and 50 ng/ml LPS for 24 hours whole cell lysate
Lane 3: Rabbit monoclonal IgG IP in THP-1 treated with 200 ng/ml IFN-gamma and 50 ng/ml LPS for 24 hours whole cell lysate
Predicted MW: 14 kDa
Observed MW: 15 kDa
免疫细胞化学
ICC analysis of THP-1 cells treated with IFN-gamma(200ng/ml,24hr) and LPS (50 ng/ml, 24hr) (top panel) and untreated THP-1 cells (below panel). Anti-CXCL9/MIG antibody was used at 1/500 dilution (Green) and incubated overnight at 4°C. Goat polyclonal Antibody to Rabbit IgG - H&L (Alexa Fluor® 488) was used as secondary antibody at 1/1000 dilution. The cells were fixed with 4% PFA and permeabilized with 0.1% PBS-Triton X-100. Nuclei were counterstained with DAPI (Blue). Counterstain with tubulin (Red).
FAQs
我们一般不推荐客户回收利用抗体。 因为抗体使用之后缓冲体系已经发生改变,不同客户在回收抗体的保存条件上也会有差异,所以抗体回收使用效果无法保证。另外,我们对一批抗体回收验证测试,测试结果显示不同抗体可回收次数不同,一般效价越高的抗体,可重复使用的次数越多,客户可根据实验情况来确定







评论(0)